MedPath

Cranberry Enhances Human Immune Function and Reduces Illness

Not Applicable
Completed
Conditions
Healthy Humans
Interventions
Dietary Supplement: Beverage made from cranberry compounds
Dietary Supplement: Beverage made to look like the cranberry beverage
Registration Number
NCT01398150
Lead Sponsor
University of Florida
Brief Summary

The purpose of this study is to determine whether consuming a beverage made with cranberry polyphenols and proanthocyanidins is effective in modifying immune function by enhancing immune cell proliferation, cytokine production, and antioxidant capacity. If immune cell proliferation is improved, the subjects are expected to have fewer cold and flu symptoms.

Detailed Description

The study will be conducted as a randomized, double blind, placebo-controlled parallel trial. Subjects will be randomly assigned to either the Treatment (cranberry beverage) group or the Placebo group and each will be instructed to consume the test beverages twice a day for 70 days. The beverage is not commercially prepared juice, but is a beverage prepared with an extract of cranberry that contains polyphenols and proanthocyanidins. Blood is taken at baseline, and day 70. Subjects are given a diary to keep a record of their cold and flu symptoms. Serum is used to determine the antioxidant activity by the ORAC method. Peripheral blood mononuclear cells are isolated from the blood draw and used fresh, cultured for 24 hours or cultured for 10 days. Freshly isolated cells will be used to determine αβ-T, γδ-T, B and NK cell numbers and then cultured in autologous serum for 10 days to determine how well they proliferate. The supernatant of 24 hour cultures will be used for cytokine determination. If cells have been primed by the beverage made with cranberry compounds, the investigators expect the cells to proliferate to a greater extent and have modified cytokine production compared to placebo. If the beverage made with cranberry compounds enhances the proliferation of one or more of these cell types (αβ-T, γδ T, B or NK cell), then it is possible that there will be fewer cold and flu symptoms in the group consuming the cranberry beverage. Incidence of illness is not expected to change, only the severity of the illness.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Health male or non-pregnant female
  • Between the ages of 21 and 50
  • BMI between 18 and 35
Exclusion Criteria
  • High blood pressure define as 140/90
  • Ongoing or chronic illness or infection
  • On hypertensive medication, immunosuppressive drugs, antibiotics, or chronic use of NSAIDS
  • Taking plant-based dietary supplements, antioxidant supplements, or probiotics
  • Vegetarian or strict vegan
  • Consume more than 1 cup of tea (iced or hot) per day
  • Consumes more than 2 glasses of alcoholic beverages per day
  • Consume more than 7 fruits and vegetables per day

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cranberry BeverageBeverage made from cranberry compounds15 ounce bottle of cranberry beverage consumed daily for 70 days
Sweetened BeverageBeverage made to look like the cranberry beveragelooks like and is given in the same way as the experimental treatment but contains no active ingredient
Primary Outcome Measures
NameTimeMethod
Physiological modifications to immune cell function70 days

Proliferation of γδ-T cells when cultured ex vivo in autologous serum

Secondary Outcome Measures
NameTimeMethod
Cold and flu symptoms70 days

Incidence and severity of cold and flu symptoms, total and individual. Other signs of severity, for example, visits to doctor or health clinic, reduction in daily activities, medications prescribed or purchased OTC.

Anti-inflammatory outcome70 days

Serum antioxidant status, cytokine production and proliferation of αβ-T, B and NK cells

Trial Locations

Locations (1)

449 Food Science and Human Nutrition Department

🇺🇸

Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath